Enanta Pharmaceuticals to Present Preclinical Data for KIT Inhibitor at AAAAI Meeting

The company's EDP-978 compound is in development for treating type 2 immune diseases.

Published on Feb. 10, 2026

Got story updates? Submit your updates here. ›

Enanta Pharmaceuticals, a clinical-stage biotechnology company, announced that preclinical data for its KIT inhibitor compound EDP-978, which is in development for the treatment of mast cell-mediated, type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

Why it matters

Enanta's EDP-978 represents a potential new treatment option for type 2 immune diseases, which are characterized by an overactive immune response and can lead to conditions like asthma, eczema, and food allergies. The presentation of preclinical data on this compound at a major allergy and immunology conference suggests progress in Enanta's efforts to develop innovative therapies for these debilitating conditions.

The details

The two poster presentations will cover the discovery of EDP-978 as a potent and selective KIT inhibitor, as well as data demonstrating its dose-dependent target engagement and favorable pharmacokinetic profile in preclinical studies, suggesting potential for once-daily dosing in humans.

  • The AAAAI Annual Meeting will be held from February 27 to March 2, 2026 in Philadelphia, PA.
  • The EDP-978 poster presentations are scheduled for Friday, February 27, 2026 from 2:45 to 3:45 PM EST.

The players

Enanta Pharmaceuticals, Inc.

A clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases.

Tessa Cressey, Ph.D.

The presenter of the poster on the discovery of EDP-978 as a potent and selective KIT inhibitor.

Yang Li, Ph.D.

The presenter of the poster on the preclinical pharmacokinetic and target engagement data for EDP-978.

Got photos? Submit your photos here. ›

What’s next

The posters presented at the AAAAI meeting will be made available on Enanta's website after the presentations on February 27, 2026.

The takeaway

Enanta's development of EDP-978, a KIT inhibitor, represents progress in the company's efforts to find new treatment options for type 2 immune diseases, which can have a significant impact on patients' quality of life.